Amanda Shreders

发表

Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment‐naïve patients with Waldenstrom macroglobulinemia

T. Habermann, D. Dingli, A. Dispenzieri, 2017, British journal of haematology.

Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab

J. Sosman, Douglas B. Johnson, I. Puzanov, 2016, Cancer Immunology Research.

Sequence of Splenectomy and Rituximab for the Treatment of Steroid-Refractory Immune Thrombocytopenia: Does It Matter?

William A. Hammond, Zhuo Li, P. Vishnu, 2019, Mayo Clinic proceedings.

Emerging therapeutic agents for lung cancer

William A. Hammond, Y. Lou, B. Dholaria, 2016, Journal of Hematology & Oncology.

Splenectomy or Rituximab in Steroid-Refractory Immune Thrombocytopenia (ITP): The Mayo Clinic Experience

William A. Hammond, Zhuo Li, P. Vishnu, 2016 .

Efficacy of immunotherapy for metastatic mucosal melanoma.

R. Joseph, Amanda Shreders, 2016, Immunotherapy.

Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia

T. Habermann, D. Dingli, S. Ansell, 2018, Annals of hematology.

Dexamethasone, Rituximab and Cyclophosphamide (DRC) As Salvage Therapy for Waldenstrom Macroglobulinemia

T. Habermann, D. Dingli, A. Dispenzieri, 2016 .

Correlation of sociodemographic and clinical parameters with depression and distress in patients with hematologic malignancies

D. Hodge, A. Chanan-Khan, S. Ailawadhi, 2018, Annals of Hematology.

No Evidence of Impact of Maraviroc on Outcome after Allogeneic Hematopoietic Stem Cell Transplant with Reduced Intensity Conditioning (RIC)

William A. Hammond, M. Heckman, V. Roy, 2016 .